Sign up Australia
Proactive Investors - Run By Investors For Investors

Ellex Medical Lasers bags $10.3M to further glaucoma surgery devices

Ellex Medical Lasers (ASX:ELX) has raised $10.3 million from a placement of shares with Australian and New Zealand investors at $1.46 per share.
Ellex Medical Lasers bags $10.3M to further glaucoma surgery devices
Ellex Medical Lasers bags $10.3M to further glaucoma surgery devices

The funds will be used to accelerate the development of Ellex’s minimally invasive glaucoma surgery device (MIGS) business focussed on the U.S. and Chinese markets.

In the U.S., this will include building a sales force of at least 15 people over the next six to nine months, up from six at the moment.

Ellex is also developing a pipeline of products to underpin its role as an emerging leader in the MIGS device market.

Furthermore, the funds will be utilised to increase surgeon engagement through clinical training and key opinion leader development across the Ellex product ranges to advance sales.

The company’s iTrack is an illuminated, micron-scale microcatheter, which enables ophthalmologists to perform canaloplasty for glaucoma patients.

The latest capital raising puts Ellex in a position to capitalise on growth opportunities for iTrack in the U.S. and Chinese markets.

Ellex’s revenue for the year ended 30 June 2016 was $73 million, a $10.1 million (16%) increase compared to the prior corresponding period.

Significantly, profit before tax for FY2016 was $4.2 million, a 61% increase from $2.6 million in FY2015.

Ellex’s share price has increased by about 56% since June 2016, last trading at $1.54.

View full ELX profile View Profile

Ellex Medical Lasers Timeline

November 30 2016

Related Articles

July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson
myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use